Literature DB >> 11377380

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

S L Winski1, E Swann, R H Hargreaves, D L Dehn, J Butler, C J Moody, D Ross.   

Abstract

To investigate the importance of NAD(P)H:quinone oxidoreductase 1 (or DT-diaphorase; NQO1) in the bioactivation of antitumor quinones, we established a series of stably transfected cell lines derived from BE human colon adenocarcinoma cells. BE cells have no NQO1 activity due to a genetic polymorphism. The new cell lines, BE-NQ, stably express wild-type NQO1. BE-NQ7 cells expressed the highest level of NQO1 and were more susceptible [determined by the thiazolyl blue (MTT) assay] to known antitumor quinones and newer clinical candidates. Inhibition of NQO1 by pretreatment with an irreversible inhibitor, ES936 [5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione], protected BE-NQ7 cells from toxicity induced by streptonigrin, ES921 [5-(aziridin-1-yl)-3-(hydroxymethyl)-1,2-dimethylindole-4,7-dione], and RH1 [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone]. RH1 was evaluated further by clonogenic assay for cytotoxic response and was more cytotoxic to BE-NQ7 cells than to BE cells. Cytotoxicity was abrogated by inhibition of NQO1 with ES936 pretreatment. Using a comet assay to evaluate DNA cross-linking, BE-NQ7 cells demonstrated significantly higher DNA cross-links than did BE cells in response to RH1 treatment. DNA cross-linking in BE-NQ7 cells was observed at very low concentrations of RH1 (5 nM), confirming that NQO1 activates RH1 to a potent cross-linking species. Further studies using streptonigrin, ES921, and RH1 were undertaken to analyze the relationship between NQO1 activity and quinone toxicity. Toxicity of these compounds was measured in a panel of BE-NQ cells expressing a range of NQO1 activity (23-433 nmol/min/mg). Data obtained suggest a threshold for NQO1-induced toxicity above 23 nmol/min/mg and a sharp dose-response curve between the no effect level of NQO1 (23 nmol/min/mg) and the maximal effect level (>77 nmol/min/mg). These data provide evidence that NQO1 can bioactivate antitumor quinones in this system and suggest that a threshold level of NQO1 activity is required to initiate toxic events.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377380     DOI: 10.1016/s0006-2952(01)00631-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

2.  Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.

Authors:  Marine Dufour; Chao Yan; David Siegel; Marie A Colucci; Matthew Jenner; Neil J Oldham; Joe Gomez; Philip Reigan; Yazhuo Li; Cristina I De Matteis; David Ross; Christopher J Moody
Journal:  Chembiochem       Date:  2011-04-19       Impact factor: 3.164

3.  NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans.

Authors:  Judith A Voynow; Bernard M Fischer; Shuo Zheng; Erin N Potts; Amy R Grover; Anil K Jaiswal; Andrew J Ghio; W Michael Foster
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-04       Impact factor: 6.914

4.  Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).

Authors:  Chao Yan; Jadwiga K Kepa; David Siegel; Ian J Stratford; David Ross
Journal:  Mol Pharmacol       Date:  2008-09-15       Impact factor: 4.436

5.  Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.

Authors:  Marie A Colucci; Philip Reigan; David Siegel; Aurélie Chilloux; David Ross; Christopher J Moody
Journal:  J Med Chem       Date:  2007-10-18       Impact factor: 7.446

6.  Riboflavin-targeted polymer conjugates for breast tumor delivery.

Authors:  Lisa M Bareford; Brittany R Avaritt; Hamidreza Ghandehari; Anjan Nan; Peter W Swaan
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

7.  Benzofuran-, benzothiophene-, indazole- and benzisoxazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.

Authors:  Jeffery J Newsome; Mary Hassani; Elizabeth Swann; Jane M Bibby; Howard D Beall; Christopher J Moody
Journal:  Bioorg Med Chem       Date:  2013-04-06       Impact factor: 3.641

8.  Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer.

Authors:  Anne M Lewis; Matthew Ough; Marilyn M Hinkhouse; Ming-Sound Tsao; Larry W Oberley; Joseph J Cullen
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

9.  NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.

Authors:  David Siegel; Jadwiga K Kepa; David Ross
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

10.  Enhancement of radiation effect using beta-lapachone and underlying mechanism.

Authors:  Ki Jung Ahn; Hyung Sik Lee; Se Kyung Bai; Chang Won Song
Journal:  Radiat Oncol J       Date:  2013-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.